Posted in | News | Medical Sensor

Rapid Pathogen Screening to Market Dry Eye Disease Detector Test Method

The Rapid Pathogen Screening, Inc. has been granted the approval of Health Canada for its RPS InflammaDry Detector. It is a ten minute, in office test that lets clinicians detect elevated levels of MMP-9 in tear fluid in patients who have Dry Eye disease. Now that RPS has the medical device license it will market the RPS InflammaDry Detector in Canada, following its recent release in Europe and Asia.

Dr. Robert Sambursky, president and chief medical officer of RPS said that receiving a Medical Device License from Health Canada for the RPS InflammaDry Detector is yet another exciting recent accomplishment for RPS.

Dry Eye was difficult to diagnose as the clinical signs of the disease are not always directly related to patient complaints. Also it was found that inflammation was often present in Dry Eye patients long before the appearance of clinical signs.

Matrix metalloproteinase-9 (MMP-9) is an inflammatory marker that has constantly been shown to be elevated in the tears of patients with Dry Eye disease. Elevated levels of MMP-9 may be a more sensitive marker than clinical signs when diagnosing Dry Eye. The RPS InflammaDry Detector needs a small sample of human tears to detect elevated levels of MMP-9.

Providing clinicians with a rapid and accurate in-office screening test to detect hidden Dry Eye disease will help identify patients that may benefit from preoperative therapy to improve their ocular surface, leading to better surgical and medical patient outcomes said Dr. Robert Sambursky.

Joel Scanlon

Written by

Joel Scanlon

Joel relocated to Australia in 1995 from the United Kingdom and spent five years working in the mining industry as an exploration geotechnician. His role involved utilizing GIS mapping and CAD software. Upon transitioning to the North Coast of NSW, Australia, Joel embarked on a career as a graphic designer at a well-known consultancy firm. Subsequently, he established a successful web services business catering to companies across the eastern seaboard of Australia. It was during this time that he conceived and launched News-Medical.Net. Joel has been an integral part of AZoNetwork since its inception in 2000. Joel possesses a keen interest in exploring the boundaries of technology, comprehending its potential impact on society, and actively engaging with AI-driven solutions and advancements.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Scanlon, Joel. (2019, February 24). Rapid Pathogen Screening to Market Dry Eye Disease Detector Test Method. AZoSensors. Retrieved on December 04, 2024 from https://www.azosensors.com/news.aspx?newsID=3186.

  • MLA

    Scanlon, Joel. "Rapid Pathogen Screening to Market Dry Eye Disease Detector Test Method". AZoSensors. 04 December 2024. <https://www.azosensors.com/news.aspx?newsID=3186>.

  • Chicago

    Scanlon, Joel. "Rapid Pathogen Screening to Market Dry Eye Disease Detector Test Method". AZoSensors. https://www.azosensors.com/news.aspx?newsID=3186. (accessed December 04, 2024).

  • Harvard

    Scanlon, Joel. 2019. Rapid Pathogen Screening to Market Dry Eye Disease Detector Test Method. AZoSensors, viewed 04 December 2024, https://www.azosensors.com/news.aspx?newsID=3186.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.